Addition of liraglutide to sleeve gastroplasty tied to superior weight loss: Study
In a recent study, Addition of liraglutide at 5 months have resulted in superior weight loss and improved efficacy as demonstrated by decreased body fat 12 months after the endoscopic sleeve gastroplasty .The interesting findings have been published in Gastroenterology.
The endoscopic sleeve gastroplasty (ESG) has been shown to be effective for inducing weight loss. Endoscopic sleeve gastroplasty (ESG) is a restrictive endoscopic bariatric procedure that provides a gastric tubulization obtained by placing full-thickness stitches. It has a double mechanism of action: the first is restriction of the gastric cavity and the second is alteration of gastric peristalsis. The result is a long-lasting feeling of satiety.
In recent years, this technique has provided excellent results: it proved to be safe (1% complication rate), quick, and statistically effective in ensuring weight loss. Inspite of this fact,very limited studies have been done in this regard.
With this background, Researchers under D Badurdeen, investigated the impact of liraglutide on percentage of total body weight loss (%TBWL), percentage of excess weight loss (%EWL), and percentage of visceral fat among patients who underwent endoscopic sleeve gastroplasty (ESG).
The study design was a retrospective study of prospectively collected data from patients undergoing ESG at 3 outpatient clinics in Brazil, between November 2017 and July 2018.Regarding the study methodology, Liraglutide was initiated 5 months after ESG in 26 patients, and 12-month outcomes were compared with patients who had ESG only. Patients that opted to take liraglutide (ESG-L) were matched 1:1 to patients that declined it (ESG). Primary outcome was percent total body weight loss (%TBWL), and percent excess weight loss (%EWL) 7 months after initiation of liraglutide (12 months after ESG). Secondary outcome was change in percent body fat 12 months after ESG. ESG technique and postprocedure follow-up was identical at all 3 sites.
On data analysis, the following facts emerged.
- Adjusted comparisons between the 2 groups showed that patients who opted to take liraglutide had a superior mean %TBWL 7 months after initiation of liraglutide (ESG-L) compared with those that declined it (ESG), 24.72 ± 2.12% versus 20.51 ± 1.68% (p <0.001).
- ESG-L had a statistically greater reduction in percent body fat compared with ESG, 7.85 ± 1.26 versus 10.54 ± 1.88 (p <0.001) at 12 months.
"Liraglutide improves the efficacy of endoscopic sleeve gastroplasty for weight loss; however, further studies are needed to evaluate the optimal dose, timing of initiation, and duration of this GLP-1 agonist."concluded the authors.
For further reference log on to:
Endoscopic Sleeve Gastroplasty Plus Liraglutide Versus Endoscopic Sleeve Gastroplasty Alone for Weight LossGastrointest. Endosc. 2020 Oct 16;[EPub Ahead of Print], D Badurdeen, AC Hoff, A Hedjoudje, A Adam, MI Itani, J Farha, S Abbarh, AN Kalloo, MA Khashab, V Singh, A Oberbach, MG Neto, S Barricello, V Kumbhari
